Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nucor Corporation (NUE) vs Twist Bioscience Corp (TWST) Price & Performance

Nucor CorporationTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

Nucor Corporation vs Twist Bioscience Corp — how do they compare? Nucor Corporation trades at $269.18 (market cap $61.93B), while Twist Bioscience Corp trades at $124.56 (market cap $7.72B). The key difference: Nucor Corporation is far larger — about 8× Twist Bioscience Corp's market cap, and Nucor Corporation pays a 0.82% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.

NUETWST
Market Cap
$61.93B$7.72B
Sector
Basic MaterialsHealth
52-Week High
$274.74$124.88
52-Week Low
$131.78$24.16
Enterprise Value
$66.34B$7.65B
Dividend Yield
0.82%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nucor Corporation

Nucor (NUE) trades at $269.50, down 1.86% on the day, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 earnings with EPS of $4.84 beating estimates of $4.46, driven by record steel mill shipments and higher prices. Revenue trends show recovery from 2024 lows, with 2026 projections indicating $36.1B revenue and improved margins. Analyst consensus remains positive with 59% buy ratings and a $279.63 price target, representing 3.8% upside potential.

Nucor presents a compelling investment case with earnings momentum, favorable analyst sentiment, and technical strength. Key opportunities include continued demand recovery and operational efficiency gains. However, risks include cyclical steel industry exposure, tariff policy uncertainties, and declining operating cash flow trends from 2022 peaks. The stock offers moderate upside to consensus targets but faces macroeconomic headwinds affecting industrial demand.

Twist Bioscience Corp

TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.

The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.

Returns comparison

Trailing returns across standard periods

About Nucor Corporation

Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.

Read more on NUE

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST